Latest Asx Listing Rules News

Australian Strategic Materials has announced the vesting of over 400,000 performance rights granted to its Managing Director and senior executives, marking a key moment in executive remuneration and potential share dilution.

Australian Bond Exchange Holdings has responded to ASX queries confirming the material impact of its involvement in the RBA's Project Acacia and acknowledged a director's breach of trading rules during a closed period.

Rhythm Biosciences is raising up to $3.75 million through a share placement to fund the launch of its ColoSTAT® colorectal cancer diagnostic and accelerate commercialization of its geneType™ portfolio.

Greenwing Resources has successfully completed its equity raising program, placing the shortfall from its Share Purchase Plan and an additional placement due to strong investor demand. This capital boost strengthens the company’s position as it advances its lithium and graphite projects.

Truscott Mining Corporation has confirmed a $577,890 capital raise through a rights issue, explaining its exploration expenditure and operational status amid a drilling hiatus since late 2022. The company underscores its commitment to long-term project development and compliance with ASX listing requirements.

My Rewards International is seeking shareholder approval to convert $2.2 million of debt into equity and launch a $3.98 million entitlement offer, key steps toward regaining its ASX listing.

Phoslock Environmental Technologies prepares for ASX reinstatement with improved sales, factory refurbishment, and ongoing legal mediation.

BPH Energy has responded to an ASX price query following unusual trading activity, confirming no undisclosed information exists and pointing to ongoing legal matters involving its investee Advent Energy as context.

Hot Chili Limited has addressed an ASX query regarding a delayed filing of a director’s interest notice, attributing the lapse to an administrative oversight while reaffirming its commitment to disclosure rules.

Nyrada Inc has responded to ASX inquiries confirming the timely and compliant disclosure of positive safety data from its Phase I clinical trial of Xolatryp. The company detailed the timeline of its awareness and release of information, affirming adherence to continuous disclosure rules.

RBR Group has successfully closed its Share Purchase Plan, raising $261,000 from shareholders, while initiating efforts to place a $329,000 shortfall over the coming months.

Thrive Tribe Technologies has raised approximately $250,000 through a discounted share placement and repaid nearly $100,000 in loans by issuing shares, aiming to bolster working capital.